Aerosolized plus Intravenous Colistin versus Intravenous Colistin Alone for the Treatment of Ventilator‐Associated Pneumonia: A Matched Case‐Control Study | Zendy

Diamantis P. Kofteridis | Zendy; Christina Alexopoulou | Zendy; Antonios Valachis | Zendy; Sofia Maraki | Zendy; Dimitra Dimopoulou | Zendy; Dimitrios Georgopoulos | Zendy; George Samonis | Zendy

Open Access

Aerosolized plus Intravenous Colistin versus Intravenous Colistin Alone for the Treatment of Ventilator‐Associated Pneumonia: A Matched Case‐Control Study

Author(s) -

Diamantis P. Kofteridis,

Christina Alexopoulou,

Antonios Valachis,

Sofia Maraki,

Dimitra Dimopoulou,

Dimitrios Georgopoulos,

George Samonis

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/657242

Subject(s) - colistin , acinetobacter baumannii , medicine , ventilator associated pneumonia , pneumonia , pseudomonas aeruginosa , incidence (geometry) , intensive care unit , antibiotics , klebsiella pneumoniae , microbiology and biotechnology , bacteria , biology , gene , biochemistry , genetics , physics , optics , escherichia coli

The incidence of ventilator-associated pneumonia (VAP) due to multidrug-resistant (MDR) organisms is increasing. Intravenous (IV) colistin or aerosolized (AS) plus IV colistin have been recently used to treat these life-threatening infections. The purpose of this study was to compare the efficacy and safety of AS plus IV colistin versus IV colistin alone for patients with MDR VAP due to gram-negative bacteria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research